司美格鲁肽综述：一种用于治疗2型糖尿病的口服胰高血糖素样肽1受体激动剂
A Review on Semaglutide: An Oral Glucagon-Like Peptide 1 Receptor Agonist in Management of Type 2 Diabetes Mellitus.
作者信息
Kalra Sanjay, Sahay Rakesh
机构信息
Department of Endocrinology, Bharti Hospital, Karnal, India.
Department of Endocrinology, Osmania Medical College, Hyderabad, India.
出版信息
Diabetes Ther. 2020 Sep;11(9):1965-1982. doi: 10.1007/s13300-020-00894-y. Epub 2020 Jul 28.
Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are a well-established class of glucose-lowering drugs. GLP-1 RAs can be classified according to their structure, duration of action and mode of administration. This review describes the basic and clinical pharmacology of orally administered semaglutide. It highlights the PIONEER clinical trial programme results, and reviews the efficacy, safety and tolerability.
胰高血糖素样肽-1受体激动剂（GLP-1 RAs）是一类成熟的降糖药物。GLP-1 RAs可根据其结构、作用持续时间和给药方式进行分类。本综述描述了口服司美格鲁肽的基础和临床药理学。它突出了“先锋”临床试验项目的结果，并对疗效、安全性和耐受性进行了综述。
Zotero 插件